Factors associated with grade progression in pancreatic neuroendocrine tumors. Read more about Factors associated with grade progression in pancreatic neuroendocrine tumors.
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Read more about Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Read more about Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Read more about Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care.
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Read more about Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Read more about Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer. Read more about MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Read more about Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Lymphovascular invasion is associated with survival for papillary thyroid cancer. Read more about Lymphovascular invasion is associated with survival for papillary thyroid cancer.
A phase II study of axitinib in advanced neuroendocrine tumors. Read more about A phase II study of axitinib in advanced neuroendocrine tumors.
